Searched for
BIOCON BIOLOGICS
Short-term headwinds, yes; owning the ecosystem is better: 20 healthcare stocks with downside risk of 23% to upside potential of 41%The healthcare sector is under scrutiny. The issue is pricing: What medicines cost and on what hospitals and the rest of the health ecosyst...- Court discharges former drug regulator S Eswara Reddy, three others in corruption caseThe court found that the call recordings relied on by the prosecution did not attribute criminality to Reddy. None of the accused, it noted...
- Biocon settles US patent dispute with Roche's Genentech, eyes 2027 Perjeta biosimilar launchBiocon announced a settlement with Genentech over its biosimilar, Pebrilzo, of the cancer drug Perjeta. The agreement allows Biocon to laun...
- Zydus moves closer to US market for Keytruda biosimilar as FDA accepts applicationZydus Lifesciences has received acceptance for its application regarding the biosimilar of Keytruda, which is a major cancer drug. The USFD...
- Existential threats join bubble fears as AI mood sobers at Singapore forumsDuring conferences in Singapore, significant apprehensions regarding the dangers of artificial intelligence emerged among investors and pol...
- When nothing is cheap, winners may come from any corner: 19 stocks with downside to upside potential of -28% to plus 22%Because each pharma company took a different road, they no longer rise and fall together. Where any one of them stands in 10 years depends ...
- Biocon arm gets positive EMA panel recommendation for breast cancerbiosimilar PebrilzoBiocon Biologics has received a positive recommendation from the European Medicines Agency’s CHMP for its Pertuzumab biosimilar, Pebrilzo, ...
- 5 stocks with consistent score improvement and upside potential of up to 22% in 1 year, according to analystsGiven the current situation both globally and domestically, one can expect more headwinds in the market. There is, on the domestic front, a...
- Agonisingly slow clinical trial is stopping Indian pharma become global innovator from supplierIndia's regulatory hurdles slow down early-stage drug trials significantly. This complexity causes Indian companies to conduct crucial firs...
- Biocon shares rise 2% on 10-year Pertuzumab supply deal for breast cancer therapy in BrazilBiocon shares rose after the company secured a 10-year Pertuzumab supply contract in Brazil. The consortium with Bahiafarma and Bionovis re...
- Biocon signs 10-year Brazil supply deal for Pertuzumab breast cancer drugIn a significant move, Biocon has secured a ten-year contract in Brazil for the distribution of Pertuzumab, made possible through its colla...
- Biocon arm gets Japan nod for cancer drug pegfilgrastim biosimilarIn a significant advancement, Biocon Biologics has gained marketing approval for its pegfilgrastim biosimilar in Japan. This vital cancer s...
- Biocon Biologics gets global rights for biosimilar AdalimumabBiocon Biologics has gained complete global rights for Hulio, a biosimilar Adalimumab. This move grants Biocon Biologics full control over ...
- Biocon Biologics mulls raising up to Rs 4,500 crore in bondsThe company is in discussions with banks for the issuance, the people said, asking not to be named because the details are private. Funds f...
- Biocon Biologics completes integration of Viatris' Europe biosimilar businessBiocon Biologics on Thursday said it has completed the integration of the acquired biosimilar business from Viatris Inc in 31 European coun...
- Biocon Biologics announces top leadership appointmentsBiocon Biologics Ltd has made several key leadership appointments, including appointing Rhonda Duffy as Chief Operating Officer and Sandeep...
- Biocon Biologics takes over Viatris' biosimilar biz in over 70 countriesBiocon Biologics on Wednesday said it has completed the integration of the acquired biosimilars business from Viatris Inc in over 70 countr...
- Biocon Biologics case: CBI seeks custodial interrogation of accusedThose arrested include a Joint Drug Controller (JDC), posted at CDSCO Headquarters, New Delhi, an executive of M/s Biocon Biologics Limited...
- CCI clears Serum Institute Life Sciences-Biocon Biologics dealOnce the deal is complete, Serum Institute Life Sciences Pvt Ltd will have about 15 per cent stake in Biocon Biologics Ltd, according to th...
- Biocon Biologics debuts in Asia IP Elite listBiocon, the Bengaluru-headquartered bio-pharma firm and the parent company for Biocon Biologics, has has been recognised as the ASIA IP ELI...
Load More
